|
Stomach Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These data indicate the pro-oncogenic potential of SNHG8 in EBV-associated GC, meaning it is a latent therapeutic target for the treatment of this type of cancer.
|
29736176 |
2018 |
|
Stomach Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The fasting blood glucose and long non-coding RNA SNHG8 predict poor prognosis in patients with gastric carcinoma after radical gastrectomy.
|
30299268 |
2018 |
|
Stomach Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Significantly, we determined that miRNA-491 was not only downregulated in stomach cancer but also inhibited GC cell progression induced by SNHG8.
|
31620977 |
2020 |
|
Stomach Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our results reveal the intertwined tumorigenesis mechanisms of lncRNA and EBV and identify SNHG8 as a highly possible candidate biomarker and drug target of gastric cancer.
|
27835598 |
2016 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Significantly, we determined that miRNA-491 was not only downregulated in stomach cancer but also inhibited GC cell progression induced by SNHG8.
|
31620977 |
2020 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
These data indicate the pro-oncogenic potential of SNHG8 in EBV-associated GC, meaning it is a latent therapeutic target for the treatment of this type of cancer.
|
29736176 |
2018 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our results reveal the intertwined tumorigenesis mechanisms of lncRNA and EBV and identify SNHG8 as a highly possible candidate biomarker and drug target of gastric cancer.
|
27835598 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Luciferase assay and Western blot assay were performed on NSCLC cells to detected the underlying mechanism of SNHG8 in NSCLC.
|
30275712 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Erratum: SNHG8 is identified as a key regulator in non-small-cell lung cancer progression sponging to miR-542-3p by targeting CCND1/CDK6 [Erratum].
|
30519042 |
2018 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Next, CCK8 assays were performed to evaluate the effects of SNHG8 on the proliferation of colorectal cancer cells and transwell assays were employed to evaluate migration and invasion.
|
31152930 |
2019 |
|
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, knockdown of SNHG8 inhibited cell proliferation, invasion, and lung metastasis in vitro and in vivo, whereas overexpression of SNHG8 reversed these effects.
|
30537734 |
2018 |
|
Acute myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
After RT-PCR validation of lncRNA SNHG8, SOCS3 and ICAM1 between the AMI and normal samples, only lncRNA SNHG8 had significant diagnostic value for further analysis.
|
31739782 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the meantime, SNHG8 acted as a molecular sponge of microRNA-411 (miR-411) in ESCC.
|
31695414 |
2019 |
|
Adenocarcinoma of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma.
|
30556854 |
2018 |
|
Endometrial Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SNHG8 expression in endometrial carcinoma tissue was significantly higher than that in normal endometrium.
|
29630089 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Meanwhile, SNHG8 expression was correlated with tumor stage and differentiation level, whereas not correlated with age, sex, tumor location and lymph node metastasis of pancreatic adenocarcinoma patients.
|
30556854 |
2018 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of lncRNA SNHG8 were dramatically increased in HCC tissues and cell lines as compared with the adjacent normal tissues, and SNHG8 expression was an independent prognostic factor of tumor recurrence in HCC patients.
|
30537734 |
2018 |
|
Epstein-Barr virus associated gastric carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of the lncRNA SNHG8 inhibits cell growth in Epstein-Barr virus-associated gastric carcinoma.
|
29736176 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Next, CCK8 assays were performed to evaluate the effects of SNHG8 on the proliferation of colorectal cancer cells and transwell assays were employed to evaluate migration and invasion.
|
31152930 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Moreover, knockdown of SNHG8 inhibited GC cell proliferation and invasion.
|
31620977 |
2020 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Functional investigation showed that ablation of SNHG8 notably restricted ESCC cell proliferation, migration, and invasion while inducing apoptosis in vitro and hindered tumor growth in vivo.
|
31695414 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Next, CCK8 assays were performed to evaluate the effects of SNHG8 on the proliferation of colorectal cancer cells and transwell assays were employed to evaluate migration and invasion.
|
31152930 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
The aggregate hazard ratio(HR) demonstrated that poor prognosis of gastric carcinoma was associated with fasting blood glucose (HR= 1.29, P=0.037), SNHG8 expression(HR = 1.10, P= 0.009), positive distant metastasis(HR = 2.99, P= 0.020), EBV positive (HR = 3.40, P=0.002), and tumor size more than 5.0 cm (HR = 3.36, P= 0.005).
|
30299268 |
2018 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
As lncRNA SNHG8 may promote HCC tumorigenesis and metastasis by sponging miR-149, it is a potential candidate marker and therapeutic target for HCC.
|
30537734 |
2018 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Our results reveal the intertwined tumorigenesis mechanisms of lncRNA and EBV and identify SNHG8 as a highly possible candidate biomarker and drug target of gastric cancer.
|
27835598 |
2016 |